Design of KYSA-8, A Phase 2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Treatment-Refractory Stiff-Person Syndrome (P2-8.018)

To evaluate the safety and efficacy of KYV-101 in patients with refractory stiff-person syndrome (SPS).

Authors

James Chung (ORCID: https://orcid.org/0000-0002-9775-0208)
Αναστασία Ζεκερίδου (ORCID: https://orcid.org/0000-0002-1960-9065)
Esther H. Nie (ORCID: https://orcid.org/0000-0002-2280-5905)
Amanda L. Piquet (ORCID: https://orcid.org/0000-0001-7349-6455)
Dominic Borie (ORCID: https://orcid.org/0009-0008-3569-2576)
Marinos C. Dalakas (ORCID: https://orcid.org/0000-0001-7070-1134)

Institutions

Thomas Jefferson University (US)
Mayo Clinic in Arizona (US)

Publication Details

Journal: Neurology
Published: 2025-04-07
DOI: https://doi.org/10.1212/wnl.0000000000210669
Citations: 2
Primary Topic: Autoimmune Neurological Disorders and Treatments
Type: article
Field-Weighted Citation Impact: 2.78

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Design of KYSA-8, A Phase 2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Treatment-Refractory Stiff-Person Syndrome (P2-8.018)

James Chung, Αναστασία Ζεκερίδου, Esther H. Nie, Amanda L. Piquet et al.

Apr 7, 2025

2 citations

Neurology

Autoimmune Neurological Disorders and Treatments

2.78

article

Design of KYSA-8, A Phase 2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Treatment-Refractory Stiff-Person Syndrome (P2-8.018)

James Chung, Αναστασία Ζεκερίδου, Esther H. Nie, Amanda L. Piquet, Dominic Borie, Marinos C. Dalakas

April 7, 2025article en

2 citations

Abstract

To evaluate the safety and efficacy of KYV-101 in patients with refractory stiff-person syndrome (SPS).

NeurologyVol. 104(7_Supplement_1)

Thomas Jefferson University (US), Mayo Clinic in Arizona (US)

Good health and well-being

Openalex Percentile: Top 11%

Autoimmune Neurological Disorders and Treatments

2.78

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Design of KYSA-8, A Phase 2, Open-Label, Multicenter Study of KYV-101, an Autologous Fully Human Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Treatment-Refractory Stiff-Person Syndrome (P2-8.018) — James Chung, Αναστασία Ζεκερίδου, et al. · Neurology (2025) | TGRS Research Map | TGRS